Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
接受一线帕博利珠单抗或西米普利单抗治疗的非小细胞肺癌患者中，高表达（50%-89%）与极高表达（≥90%）的程序性死亡配体1（PD-L1）患者的三年总生存期结果及相关性分析
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2024.100675
Ricciuti, Biagio; Elkrief, Arielle; Lin, Jessica; Zhang, Jianjun; Alessi, Joao V; Lamberti, Giuseppe; Gandhi, Malini; Di Federico, Alessandro; Pecci, Federica; Wang, Xinan; Makarem, Maisam; Hidalgo Filho, Cassio Murilo; Gorria, Teresa; Saini, Arushi; Pabon, Cindy; Lindsay, James; Pfaff, Kathleen L; Welsh, Emma L; Nishino, Mizuki; Sholl, Lynette M; Rodig, Scott; Kilickap, Saadettin; Rietschel, Petra; McIntyre, Debra Ag; Pouliot, Jean-Francois; Altan, Mehmet; Gainor, Justin F; Heymach, John V; Schoenfeld, Adam J; Awad, Mark M
